Decoding the Brain for Tomorrow's Treatments

At Inscopix, we seek to unlock human potential by developing advanced technologies and quantitative neural circuit-based approaches to understand the brain in health and to heal it in disease.

Positioned at the intersection of neuroscience, technology, and community, we work with stakeholders across sectors- academia, biopharmaceutical industry, philanthropy, and government- to catalyze and translate deep scientific insights into new therapies for people living with debilitating neurological and psychiatric illnesses such as depression, Parkinson's, Alzheimer's, and PTSD.

 

Company Snapshot

491

LABS SERVED

1179

SYSTEMS INSTALLED

155

CITED PUBLICATIONS

Mountain View, California

HEADQUARTERS

Recognition

In 2016, Inscopix was ranked #61 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology and media companies in North America.

Read Press Release

In 2015, the World Economic Forum recognized Inscopix as a Technology Pioneer, an honor that it bestows on a selection of the world’s most innovative young companies.

Learn More

In 2014, the White House recognized Inscopix as an industry partner of the Presidential BRAIN Initiative. Inscopix supported the initiative through its $2 million DECODE Grant Program.

Read Full Article

In 2013, The Scientist magazine ranked Inscopix’s miniature microscope as the #1 life science innovation, calling it a “major disruptive event in the history of neuroscience”.

Read More

Milestones

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2021

nVue System

Inscopix launches the nVue System for dual-color miniscope imaging during free behavior, which is The Scientist's #1 innovation for the year.

2020

Scientific Thought Leadership in a Challenging Year

The company rapidly transitions to an all-virtual thought leadership program for the socially and scientifically distanced neuroscience community, notably with the Insights Webinars and the DECODE 2020 Summit.

2019

Translational efforts gather momentum

Inscopix launches two pharma collaborations with Biogen (in the area of chronic pain) and Astellas (in the area of psychiatric disorders). The first successful application of Inscopix platforms into non-human primate models is published.

2018

Scaling up

The user base expands to over 250 laboratories with over 425 Systems in the field. The Inscopix community publishes over 50 peer-reviewed original research articles in top-tier journals, with 2 publications using the nVoke System.

2017

The complete solution begins to form

Inscopix launches the nVista 3.0 System and the nVoke 2.0 System compatible with a new commutator. We also launched ready-to-image viruses and the Inscopix Data Processing Software (IDPS) towards offering users a complete workflow.

2016

nVoke System

The company launches a second product, nVoke System, for integrated brain activity imaging and manipulation at the annual SFN meeting.

2015

A growing user base

Inscopix community grows to over 100 laboratories across the globe. These include 6 Nobelists and 23 HHMI investigators. First research article outside the founders lab is published in the top-tier journal Cell.

2014

Building the infrastructure

Inscopix builds its manufacturing facility at the Mountain View headquarters and biological R&D labs in Mountain View for application development, training, and scientific research.

2013

First Systems shipped

The first nVista Systems are sent to customers's laboratories at Pfizer and the Howard Hughes Medical Institute (HHMI).

2012

nVista System

Inscopix launches nVista, a commercial grade miniature microscope-based brain imaging system for plug-and-play neural activity mapping at the Society for Neuroscience (SfN) Meeting.

2011

Founding

Inscopix is founded by Drs. Kunal Ghosh, Mark Schnitzer, and Abbas El Gamal to commercialize the Stanford miniature microscope invention. The company receives seed financing from Floodgate and Fidelity Biosciences.